Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Positive results from study comparing exenatide once weekly to BYETTA

Positive results from study comparing exenatide once weekly to BYETTA

People with periodontal disease are at high risk for diabetes, survey finds

People with periodontal disease are at high risk for diabetes, survey finds

Tea and coffee can reduce risk of type 2 diabetes

Tea and coffee can reduce risk of type 2 diabetes

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

Kaiser Permanente: Women of Chinese and Korean heritage may develop diabetes during pregnancy

Kaiser Permanente: Women of Chinese and Korean heritage may develop diabetes during pregnancy

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

2009 Ward Burdick Award for UAB Director

2009 Ward Burdick Award for UAB Director

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Roche announces results of phase III taspoglutide study in diabetes patients

Roche announces results of phase III taspoglutide study in diabetes patients

LeapFrog Investments announces ZAR 50 million investment in AllLife

LeapFrog Investments announces ZAR 50 million investment in AllLife

Drinking sugar-sweetened cola a week prior to pregnancy elevates diabetes during pregnancy

Drinking sugar-sweetened cola a week prior to pregnancy elevates diabetes during pregnancy

European Commission approves MICARDIS medication for CV protection

European Commission approves MICARDIS medication for CV protection

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Wnt signaling pathway plays a role in diabetic retinopathy

Wnt signaling pathway plays a role in diabetic retinopathy

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ESC and EASD organize Joint Scientific Forum in China to address optimal treatment strategies for diabetes

ESC and EASD organize Joint Scientific Forum in China to address optimal treatment strategies for diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.